Clinical trial
Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056)
NCT00322361 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00322361 |
|---|---|
| Title | Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056) |
| Official title | A Study in Healthy Neonates of Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured Using a Modified Process |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis B, Hepatocellular Carcinoma |
| Intervention type | Biological |
| Interventions | Comparator: RECOMBIVAX HB™, Comparator: Modified process Hepatitis B Vaccine |
| Enrollment | 566 |
| Start date | May 1, 2006 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | May 5, 2006 |
| Last update posted | Mar 16, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: